IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES

Cabilly et al	)	
	)	Interference No. 102,572
v.	)	
	)	Examiner-in-Chief
Boss et al	)	Mary F. Downey

DECLARATION OF MICHAEL REY

1. I, Michael Rey, declare and state that I am a citizen of the United States residing in San Mateo, California. My Curriculum Vitae is attached as Cabilly Exhibit No. 14.

2. From December 15, 1980 until April, 20, 1984, I was a Research Assistant at Genentech, Inc. (Genentech) located at 460 Point San Bruno Blvd., South San Francisco, California. During that time I reported to Dr. Herb Heyneker. I am presently employed by Genencor, Inc. as a Senior Research Associate, in South San Francisco, California.

3. It was my general practice to date my notebooks on the date the work was done. I began my involvement in the project to express antibodies directed against human carcinoembryonic antigen in bacteria in July, 1982. I had received microtiter dishes with cultures that contained cDNA from the hybridoma cell line CEA-66-E3. I transferred these arrayed cultures to agar plates and allowed them to grow. I later transferred the colonies in duplicate, to nitrocellulose filters, layered them onto agar plates and incubated them at 37°C. Once these colonies had sufficiently grown, I lysed the colonies on these filters and treated them for subsequent probing (Cabilly Exhibit No. 15, Bates Nos. 00502 and 00504).

4. I assisted in the sequencing of the heavy chain cDNA by subcloning DNA into M13 vectors, preparing single-stranded template and carrying out the sequencing reactions. I also assisted in the sequencing of the heavy and light chain cDNA's (Cabilly Exhibit No. 15, Bates No. 00509-00516, 00521, 00522, 00528, and 00531).

5. I sequenced a PstI to AvaII DNA fragment of the light chain following a primer repair reaction that introduced an initiation codon into this sequence (Cabilly Exhibit No. 15, Bates No. 00530).

6. I prepared the plasmids pKCEAtrp207-1* by digesting pKCEAInt2 with AvaI, filling in, digesting with PstI and isolating the fragment by PAGE. The vector fragment was prepared by digesting pBR322(XAP) with EcoRI, filling in, and redigesting with PstI followed by fragment isolation by PAGE. This fragment was also used in the construction of pGammaCEAtrp207-1*. The purified fragments were ligated, transformed into E.coli and analyzed by restriction digests to identify positive colonies (Cabilly Exhibit No. 15, Bates Nos. 00533-00537).

7. William Holmes and I analyzed several tetracycline resistant transformants from the pGammaCEAFABtrp207-1* ligation by restriction analysis and sequencing (Cabilly Exhibit No. 13, Bates Nos. 00885-00887, 00889; Cabilly Exhibit 15, Bates Nos. 00541, 00543, and 00544).

8. I further declare that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Michael Rey

Dated: 10/25/91

GNE-MED-02032

GNE-GSK00003435

GNE-HGS 00082046